| dbo:abstract |
Le rociletinib est une molécule inhibitrice du récepteur de l'EGF, et par ce biais, de la tyrosine kinase et en cours de test comme médicament dans le traitement de certains cancers. (fr) Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. It was being developed by Clovis Oncology as a potential treatment for non-small-cell lung cancer. In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew its marketing authorisation application from the European Medicines Agency. (en) |
| dbo:alternativeName |
Xegafri (en) |
| dbo:casNumber |
1374640-70-6 |
| dbo:drugbank |
DB11907 |
| dbo:fdaUniiCode |
72AH61702G |
| dbo:kegg |
D10858 |
| dbo:pubchem |
57335384 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Rociletinib.svg?width=300 |
| dbo:wikiPageID |
50053932 (xsd:integer) |
| dbo:wikiPageLength |
3162 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1031201275 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Epidermal_growth_factor_receptor dbr:Non-small_cell_lung_carcinoma dbc:Abandoned_drugs dbc:Trifluoromethyl_compounds dbr:Oral_administration dbr:Clovis_Oncology dbc:Experimental_cancer_drugs dbr:Tyrosine_kinase_inhibitor dbr:Drug_development dbr:European_Medicines_Agency dbc:Receptor_tyrosine_kinase_inhibitors dbc:Acrylamides dbr:Non-small-cell_lung_cancer dbr:Marketing_authorisation_application |
| dbp:atcPrefix |
L01 (en) |
| dbp:atcSuffix |
EB05 (en) |
| dbp:c |
27 (xsd:integer) |
| dbp:casNumber |
1374640 (xsd:integer) |
| dbp:chemspiderid |
30646712 (xsd:integer) |
| dbp:drugbank |
DB11907 (en) |
| dbp:f |
3 (xsd:integer) |
| dbp:h |
28 (xsd:integer) |
| dbp:iupacName |
N-acrylamide (en) |
| dbp:kegg |
D10858 (en) |
| dbp:n |
7 (xsd:integer) |
| dbp:o |
3 (xsd:integer) |
| dbp:pubchem |
57335384 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:smiles |
CCN1CCNc2cccNc3nccCF (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
HUFOZJXAKZVRNJ-UHFFFAOYSA-N (en) |
| dbp:synonyms |
CO-1686, AVL-301 (en) |
| dbp:tradename |
Xegafri (en) |
| dbp:unii |
72 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Antineoplastic-drug-stub dbt:Infobox_drug dbt:Reflist dbt:Short_description dbt:Growth_factor_receptor_modulators dbt:Targeted_cancer_therapeutic_agents |
| dct:subject |
dbc:Abandoned_drugs dbc:Trifluoromethyl_compounds dbc:Experimental_cancer_drugs dbc:Receptor_tyrosine_kinase_inhibitors dbc:Acrylamides |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Le rociletinib est une molécule inhibitrice du récepteur de l'EGF, et par ce biais, de la tyrosine kinase et en cours de test comme médicament dans le traitement de certains cancers. (fr) Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. It was being developed by Clovis Oncology as a potential treatment for non-small-cell lung cancer. In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew its marketing authorisation application from the European Medicines Agency. (en) |
| rdfs:label |
Rociletinib (fr) Rociletinib (en) |
| owl:sameAs |
wikidata:Rociletinib dbpedia-fr:Rociletinib https://global.dbpedia.org/id/2cvrS |
| prov:wasDerivedFrom |
wikipedia-en:Rociletinib?oldid=1031201275&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Rociletinib.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Rociletinib |
| is dbo:wikiPageWikiLink of |
dbr:Institute_for_Clinical_and_Economic_Review dbr:Clovis_Oncology dbr:ATC_code_L01 dbr:Aurora_kinase_A |
| is foaf:primaryTopic of |
wikipedia-en:Rociletinib |
